Targeted therapy in brain metastasis.

Area of Science:

• Oncology
• Neuro-oncology
• Pharmacology

Background:

• Brain metastases represent a significant challenge in cancer care.
• Advances in understanding molecular pathways driving brain colonization are crucial.

Purpose of the Study:

• To review the current state and new developments in targeted agents for brain metastases.
• To explore the potential of targeted therapies in both treatment and prevention settings.

Main Methods:

• Review of preclinical and clinical investigations.
• Analysis of data from clinical trials on targeted agents.

Main Results:

• Targeted therapies, including antiangiogenic agents, tyrosine kinase inhibitors (TKIs), EGFR inhibitors, and immunomodulators, show activity in brain metastases.
• Bevacizumab (anti-VEGF) is under investigation for various cancers.
• Sunitinib shows promise for renal cell carcinoma brain metastases.
• Gefitinib and erlotinib are active in EGFR-mutated NSCLC brain metastases.
• Lapatinib is active in HER2-positive breast cancer brain metastases.
• Vemurafenib is effective for BRAF V600E melanoma brain metastases.
• Ipilimumab is active in melanoma brain metastases.

Conclusions:

• Targeted agents offer a promising approach for managing brain metastases from solid tumors.
• The role of targeted therapies in prevention is expected to expand.
• Well-designed clinical trials with appropriate endpoints are essential for future progress.